Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis

Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States

This study is a single-site trial assessing the specificity of CL Detect™ Rapid Test versus the gold standard for Leishmania diagnosis in the US which is microscopic identification of Leishmania amastigotes in a stained lesion sample.

Study Overview

• Status: Completed
• Conditions: Skin Diseases

Detailed Description

Subjects will be patients who present for dermatology consultation with a primarily ulcerated lesion. After informed consent is obtained and the subject is screened for eligibility, 2 diagnostic samples will be collected from the subject's lesion in the following order: 1) one sample will be obtained with a dental broach for use with the CL Detect™ Rapid Test and 2) a second sample will be obtained by scraping for use in the microscopic identification of amastigotes. Samples will be analyzed by microscopy and CL Detect™ Rapid Test. The CL Detect™ Rapid Test will be performed by different operators who are clinical staff members. These staff members, blinded to each other's results, will evaluate the samples from each method independently. Each of the 150 study subjects will be followed administratively to the point where a diagnosis is established (if possible) for their tested lesion, even if that diagnosis is not cutaneous leishmaniasis (CL). If a specific diagnosis cannot be determined for a non-CL lesion, the investigator will assign a "likely etiology" (eg, infectious, oncological, immunological, vascular, or "undetermined/other" origin). Based on the diagnosis determined for each lesion, subjects will be referred for appropriate treatment.

• Study Type: Observational
• Enrollment (Actual): 150

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Dermatology clinic

Description

Inclusion Criteria:

• At least 18 years of age
• Subject is able to give written informed consent
• Subject has a skin ulcer that satisfies the following criteria for an index lesion:
• less than 4 months in age
• primarily ulcerative, not purely verrucous or nodular, and does not have clear clinical evidence of cellulitis
• in a location suitable for collecting samples by dental broach and scraping
• In the opinion of the investigator, the subject is capable of understanding and complying with the protocol

Exclusion Criteria:

• Received treatment for leishmaniasis or any treatment to the lesion even if not previously diagnosed as leishmaniasis such as azoles, cryotherapy, imiquimod, thermotherapy, photodynamic therapy, within 2 months prior to signing the consent form, with the exception of mercurochrome

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Skin Ulcers; Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
True Positive	Positive by both the CL Detect™ Rapid Test and microscopy of an index lesion smear for amastigotes.	within 1 hour after samples are taken
False Positive	Positive by the CL Detect™ Rapid Test but negative for Microscopy	within 1 hour after samples are taken
True Negative	Negative by both the CL Detect™ Rapid Test device and Microscopy	within 1 hour after samples are taken
False Negative	Negative by the CL Detect™ Rapid Test but positive for Microscopy	within 1 hour after samples are taken
Specificity	Negative Specificity was calculated as the number of true negatives divided by the sum of the number of true negatives plus the number of false positives.	within 1 hour after samples are taken
False Positive Rate	False positive rate (type 1 error, calculated as 1-specificity)	within 1 hour after samples are taken

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
False positive rate	α, type 1 error, calculated as 1-specificity times 100%	1 hour
False negative rate	β, type 2 error, calculated as 1-sensitivity times 100%	1 hour

Collaborators and Investigators

• Sponsor: U.S. Army Medical Research and Development Command
• Collaborators: InBios International, Inc.
• Investigators: Principal Investigator: Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2013
• Primary Completion (Actual): August 1, 2013
• Study Completion (Actual): April 1, 2014

Study Registration Dates

• First Submitted: May 23, 2013
• First Submitted That Met QC Criteria: May 28, 2013
• First Posted (Estimated): May 30, 2013

Study Record Updates

• Last Update Posted (Actual): February 25, 2026
• Last Update Submitted That Met QC Criteria: February 4, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Leishmaniasis, Leishmania
• Additional Relevant MeSH Terms: Vector Borne Diseases; Infections; Protozoan Infections; Parasitic Diseases; Skin Diseases, Infectious; Skin Diseases, Parasitic; Euglenozoa Infections; Skin and Connective Tissue Diseases; Skin Diseases; Leishmaniasis
• Other Study ID Numbers: S-12-19

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED